



(51) International Patent Classification:

C07D 499/87 (2006.01) A61P 31/04 (2006.01)
A61K 31/431 (2006.01)

(21) International Application Number:

PCT/EP2014/074108

(22) International Filing Date:

7 November 2014 (07.11.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1319776.9 8 November 2013 (08.11.2013) GB
1408643.3 15 May 2014 (15.05.2014) GB

(71) Applicant: ALLECRA THERAPEUTICS SAS [FR/FR];
13 rue Village Neuf, F-68300 Saint Louis (FR).

(72) Inventors: LAMONICA, Alessandro; c/o Allecra Therapeutics SAS, 13 rue Village Neuf, F-68300 Saint Louis (FR). FORZATTI, Marco; c/o Allecra Therapeutics SAS, 13 rue Village Neuf, F-68300 Saint Louis (FR). BIONDI, Stefano; c/o Allecra Therapeutics SAS, 13 rue Village Neuf, F-68300 Saint Louis (FR).

(74) Agents: GILANI, Anwar et al.; Venner Shipley LLP, Byron House, Cambridge Business Park, Cowley Road, Cambridge Cambridgeshire CB4 0WZ (GB).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: CRYSTALLINE BETA-LACTAMASE INHIBITOR



(57) Abstract: A crystalline compound of formula (I): Formula (I). The compound of formula (I) is a β -lactamase inhibitor and may be administered in combination with an antibacterial agent for prevention or treatment of bacterial infection.